In patients aged ≥75 years, lipid-lowering therapy was as effective in reducing cardiovascular events as it was in patients <75 years. A 26% reduction was seen in major events per 1 mmol/L reduction of low-density lipoprotein (LDL) cholesterol. These results from a systematic review and meta-analysis should strengthen guideline recommendations for the use of lipid-lowering therapies in older patients .
Dr Baris Gencer (Brigham and Women’s Hospital, USA) presented a systematic review and meta-analysis, which included 24 trials from the Cholesterol Treatment Trialists’ Collaboration meta-analysis, as well as 5 randomised controlled cardiovascular outcome trials, all recently published (2015–2020). The results were simultaneously published in T...
If you have no account yet, please
Please login to read the full text of the article.
« No CV benefit from omega 3 in high-risk patients Next Article
Polypill plus aspirin reduces cardiovascular events »
Table of Contents: AHA 2020
COVID-19 and Influenza
CVD Risk Reduction
Acute Coronary Syndrome
Coronary and Valve Disease
If you have no account yet, please register now.